

## Amendments to the Specification

Please replace the paragraph at page 4, line 26 through page 5, line 8 with the following amended paragraph:

Figure 2 is a graph showing inhibition of chronic vasculopathy in transplanted hearts in a model consisting of only fully mismatched mice greater than 100 days following heart transplant. The graph compares inhibition of chronic vasculopathy in a group of mice treated with a single 250  $[[\mu\text{m}]]\mu\text{g}$  dose of anti-CD154 monoclonal antibody immediately following heart transplant surgery with a group of mice treated with a single 250  $[[\mu\text{m}]]\mu\text{g}$  dose of anti-CD154 immediately following heart transplant surgery and 75 mg/kg of Compound 1 subcutaneously for fourteen days after heart transplant surgery. The scores shown in the graph range from zero to five to indicate the severity of chronic rejection accelerated atherosclerosis, with zero being normal blood vessel and five being fully occluded.

Please replace the paragraph at page 14, lines 9 through 14 with the following amended paragraph:

- a)  $R_2$  is an optionally substituted 2-(imidazol-4-yl)ethyl, an optionally substituted 3-(imidazol-4-yl)propyl, an optionally substituted 3-(imidazol-1-yl)propyl, an optionally substituted 2-(morpholin-4-yl)ethyl, an optionally substituted 2-(4-pyrazolyl)ethyl, an optionally substituted 2-*N,N*-dimethylaminoethyl or an optionally substituted 3-*N,N*-dimethylaminopropyl. Preferably,  $R_2$  is 2-(imidazol-4-yl)ethyl.